Meksiprim injection 50mg / 5ml ampoules 5 ml Pieces

Description

Composition
Active substance:
1 ml of solution
Emoxypine – 50 mg.
Excipients:
Water for injection – up to 1 ml.
Description:
Colorless or slightly yellowish transparent liquid.
Product form:
Solution for intravenous and intramuscular use 50 mg / mL.
5 mL neutral glass ampoules. 5 ampoules in blisters from a film of PVC or polyvinyl chloride film and aluminum foil. 1 contour cellular packaging with instructions for medical use of the drug, with a knife or lancet ampoule is placed in a pile of cardboard.
Contraindications
Acute hepatic and / or renal insufficiency, increased individual sensitivity to the drug. Children’s age, pregnancy, breast-feeding – the action of the drug in these categories of patients due to insufficient knowledge.
Dosage
50 mg / ml
Indications
Acute ischemic attacks (in the complex therapy);
Encephalopathy;
Vascular dystonia;
Anxiety neurosis and neurotic at conditions;
Mild cognitive disorders of various origins (psychoorganic and asthenic syndromes, consequences of traumatic brain injury, atherosclerosis, and senile atrophic processes, and CNS toxicity);
Memory disorders and intellectual impairment in the elderly;
Exposure to extreme (stress) factors;
Abstinence syndrome in alcoholism with predominance neurosis and vegetative-vascular disorders;
Acute intoxication with antipsychotic drugs.
Interaction with other drugs
Meksiprim compatible with psychotropic drugs; It enhances the effect of benzodiazepine anxiolytics, antiparkinsonian and carbamazepine. Reduces the toxic effects of ethanol.
Overdose
Symptoms: sleep disturbance (insomnia, in some cases – drowsiness).
Treatment: as a rule, does not require – the symptoms disappear on their own within a day.
In severe cases of insomnia are advised to take sleeping pills.
pharmachologic effect
Pharmacological group:
Anti-oxidant agent.
Pharmacodynamics:
Meksiprim refers to heteroaromatic antioxidants. It has a wide spectrum of pharmacological activities: increases resistance to stress, exhibits anxiolytic effect is not accompanied by drowsiness and muscle relaxant effect; It possesses nootropic properties, prevents and reduces disorders of learning and memory, resulting in aging and exposure to various pathogens; having anticonvulsant activity; exhibits antihypoxic and antioxidant properties; It improves concentration and performance; It weakens the toxic effect of alcohol.
Preparation improves brain tissue metabolism and blood circulation, improve microcirculation and blood rheology, reduce platelet aggregation. It stabilizes the membrane structure of blood cells (erythrocytes and platelets). It has hypolipidemic effect, reduces total cholesterol and low density lipoproteins.
Meksiprima action mechanism is due to its antioxidant and membrane action. It inhibits lipid peroxidation, increases the activity superoksidoksidazy, increases the ratio of lipid-protein membrane reduces viscosity and increases its fluidity. Modulates the activity of membrane enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase) receptor complexes (benzodiazepine, GABA, acetylcholine) that enhances their ability to bind to ligands, helps to preserve the structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission. Meksiprim increases in the brain, dopamine. Causes increased activation of compensatory aerobic glycolysis and decreased inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, energosinteziruyuschih activation of mitochondrial functions, stabilization of cell membranes.
Pharmacokinetics:
Meksiprima size maximum plasma concentration is in the range from 50 to 100 ng / ml.
Meksiprima half-life and mean residence time of the drug in the body are respectively 4.7-5.0 h and 4.9-5.2 h. Meksiprim in the human body is extensively metabolized to form his glyukuronokonyugirovannogo product. On average, 12 hours urine excreted unchanged drug 0.3% and 50% of the administered dose glyukuronokonyugata. The most intense and Meksiprim glyukuronokonyugat excreted within the first 4 hours after ingestion. Indicators excretion Meksiprima and its conjugated metabolites have significant individual variability.
Conditions of supply of pharmacies
On prescription.
side effects
Rarely – nausea, dryness of the oral mucosa, drowsiness, allergic reactions.
special instructions
During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In the dark place at a temperature not higher than 20 ° C.
Keep out of the reach of children.
Dosing and Administration
Meksiprim administered intramuscularly or intravenously (bolus or infusion). Doses are selected individually. When the infusion method of administering the drug should be diluted in physiological sodium chloride solution. Started treatment with doses of 50-100 mg of 1 -3 times a day, gradually increasing the dose until a therapeutic effect. Chip Meksiprim introduced slowly over 5-7 minutes, dropwise – at a rate of 40-60 drops per minute. The maximum daily dose will not exceed 800 mg.
In acute cerebrovascular disorders Meksiprim used in the treatment in the first 2-4 days of intravenous infusion of 200-300 mg 1 time per day, then intramuscular injection of 100 mg 3 times a day. The duration of treatment is 10-14 days.
In vascular encephalopathy in phase decompensation Meksiprim should be administered intravenous bolus or infusion in a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intramuscularly, 100 mg 2-3 times a day over the next two weeks. vascular encephalopathy drug for preventing exchange administered intramuscularly at a dose of 100 mg 2 times a day for 10-14 days.
For mild cognitive impairment in elderly patients and in anxiety disorders, drug use by intramuscular injection at a daily dose of 100-300 mg per day for 14-30 days.
When alcohol withdrawal syndrome Meksiprim administered in a dosage of 100-200 mg intramuscularly, 2-3 times a day or intravenously 1-2 times a day for 5-7 days.
In acute intoxication antipsychotics preparation is administered intravenously at a dose of 50-300 mg per day for 7-14 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist